Compare WAB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAB | NTRA |
|---|---|---|
| Founded | 1869 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6B | 47.4B |
| IPO Year | 1996 | 2015 |
| Metric | WAB | NTRA |
|---|---|---|
| Price | $286.53 | $401.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 23 |
| Target Price | $330.00 | ★ $383.66 |
| AVG Volume (30 Days) | 519.9K | ★ 1.7M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 13.08 | 0.65 |
| EPS | ★ 4.44 | N/A |
| Revenue | ★ $2,391,122,000.00 | $210,939,000.00 |
| Revenue This Year | $12.35 | $26.17 |
| Revenue Next Year | $7.23 | $20.65 |
| P/E Ratio | $63.24 | ★ N/A |
| Revenue Growth | ★ 21.52 | N/A |
| 52 Week Low | $186.06 | $169.50 |
| 52 Week High | $306.64 | $437.41 |
| Indicator | WAB | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 61.52 |
| Support Level | $253.56 | $187.64 |
| Resistance Level | $304.63 | N/A |
| Average True Range (ATR) | 5.88 | 17.33 |
| MACD | -0.28 | -3.35 |
| Stochastic Oscillator | 58.92 | 50.04 |
Westinghouse Air Brake Technologies Corp provides value-added, technology-based products and services for the freight rail and passenger transit industries and the mining, marine, and industrial markets. It provides its products and services through two main business segments: Freight and Transit. The company generates maximum revenue from the Freight segment, which manufactures new and modernized locomotives, provides aftermarket parts and services to existing locomotives, provides components to new and existing freight cars; builds new commuter locomotives; supplies rail control and infrastructure products, including electronics, positive train control equipment, signal design, and engineering services. Geographically, it generates a majority of its revenue from the United States.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.